financetom
Business
financetom
/
Business
/
Tempus Reports 83% Growth in Preliminary Q4 Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tempus Reports 83% Growth in Preliminary Q4 Revenue
Mar 11, 2026 12:19 AM

03:31 AM EST, 01/12/2026 (MT Newswires) -- Tempus AI ( TEM ) reported Sunday preliminary Q4 revenue of $367 million, up 83% from a year earlier.

Analysts polled by FactSet are expecting $360 million.

Diagnostics revenue for the quarter grew 121% to $266 million, while data and applications revenue increased 25% to about $100 million, the company said.

The company plans to report full Q4 financial results in February.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Fathom Holdings Prices Underwritten Public Offering of Common Stock
Fathom Holdings Prices Underwritten Public Offering of Common Stock
Sep 21, 2025
CARY, N.C., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. ( FTHM ) , a national, technology-driven real estate services platform, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase...
Syndax's Revumenib Added to National Cancer Guidelines for NPM1-Mutant Acute Myeloid Leukemia
Syndax's Revumenib Added to National Cancer Guidelines for NPM1-Mutant Acute Myeloid Leukemia
Sep 21, 2025
08:05 AM EDT, 09/19/2025 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) said Friday the National Comprehensive Cancer Network included its blood cancer drug Revuforj, or revumenib, as a category 2A recommendation in the Clinical Practice Guidelines in Oncology for relapsed or refractory acute myeloid leukemia with an NPM1 mutation, an aggressive blood cancer associated with high rates of relapse....
Aurion Completes $743,400 Private Placement with Kinross to Maintain 9.99% Stake
Aurion Completes $743,400 Private Placement with Kinross to Maintain 9.99% Stake
Sep 21, 2025
08:11 AM EDT, 09/19/2025 (MT Newswires) -- Aurion Resources ( AIRRF ) said Friday that it completed its previously announced private placement of units with Kinross Gold ( KGCRF ) , resulting in Kinross maintaining its ownership position of 9.99% on a partially diluted basis. Under the terms, Aurion issued 885,000 units at $0.84 each for $743,400 in proceeds. Each...
Neo Signs MOU to Reserve Major Magnet Production Capacity for Bosch
Neo Signs MOU to Reserve Major Magnet Production Capacity for Bosch
Sep 21, 2025
08:03 AM EDT, 09/19/2025 (MT Newswires) -- Neo Performance Materials ( NOPMF ) said Friday it has signed a Memorandum of Understanding with Robert Bosch, agreeing to reserve a significant annual magnet production capacity for the global company. The MOU also outlines a clear mutual target for the partners to transition the capacity reserve into definitive projects, a statement said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved